8-K: Merck Reports Mixed Q4 and Full-Year 2023 Results Amidst Restructuring and Strategic Investments

Merck's fourth-quarter and full-year 2023 results show sales growth driven by oncology and vaccines, but are impacted by a significant charge related to a collaboration with Daiichi Sankyo and restructuring costs.

Summary

• Merck's fourth-quarter worldwide sales reached $14.6 billion, a 6% increase compared to the same period in 2022, or 13% excluding the impact of LAGEVRIO and foreign exchange.
• Full-year worldwide sales were $60.1 billion, a 1% increase from 2022, or 12% excluding LAGEVRIO and foreign exchange.
• Key growth drivers included KEYTRUDA, with sales up 19% to $25.0 billion for the year, and GARDASIL/GARDASIL 9, with sales up 29% to $8.9 billion.
• LAGEVRIO sales declined significantly by 75% to $1.4 billion for the full year.
• The company reported a GAAP loss per share of $0.48 for the fourth quarter and $0.14 for the full year, impacted by a $1.69 per share charge for a collaboration with Daiichi Sankyo and $6.21 per share for certain business development transactions.
• Non-GAAP EPS was $0.03 for the fourth quarter and $1.51 for the full year.
• Merck approved a new restructuring program expected to cost approximately $4.0 billion pretax, with 60% being non-cash charges.
• The company anticipates full-year 2024 sales to be between $62.7 billion and $64.2 billion and non-GAAP EPS to be between $8.44 and $8.59.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there is strong growth in key areas like oncology and vaccines, the significant charges, restructuring costs, and decline in LAGEVRIO sales temper the positive aspects. The forward-looking guidance is positive, but the current results are mixed.

Positives

• Strong growth in oncology, particularly with KEYTRUDA, and vaccines, especially GARDASIL/GARDASIL 9.
• Excluding LAGEVRIO and foreign exchange, sales growth was robust.
• The company is actively advancing its pipeline with multiple Phase 3 trial initiations.
• FDA Priority Review was granted for key pipeline candidates.
• The company is making strategic acquisitions and collaborations to augment its pipeline.
• The company reached more than 500 million people with its medicines last year alone, over half of which were donations.

Negatives

• Significant decline in LAGEVRIO sales impacted overall revenue growth.
• GAAP earnings were significantly impacted by charges related to collaborations and business development transactions.
• The new restructuring program will incur substantial costs.
• The company experienced a GAAP loss per share for the fourth quarter and a low EPS for the full year.
• The effective tax rate was high for both the fourth quarter and full year due to charges for asset acquisitions and the Daiichi Sankyo collaboration.

Risks

• The restructuring program may present operational challenges and incur higher than expected costs.
• Dependence on the success of pipeline candidates and their regulatory approvals.
• The company is exposed to currency exchange rate fluctuations, particularly with the devaluation of the Argentine peso.
• The company is exposed to litigation, including patent litigation, and/or regulatory actions.
• The company is exposed to general industry conditions and competition.

Future Outlook

Merck anticipates full-year 2024 sales to be between $62.7 billion and $64.2 billion, with non-GAAP EPS between $8.44 and $8.59. The outlook includes the impact of the Harpoon Therapeutics acquisition and a negative impact from foreign exchange.

Management Comments

• Robert M. Davis, chairman and chief executive officer, stated that 2023 was a very strong year for Merck.
• He expressed pleasure in the progress made to develop and deliver transformative therapies and vaccines.
• He highlighted the company's reach of over 500 million people with medicines, including donations.
• He mentioned investments of approximately $30 billion in research and development.
• He expressed confidence that the company's strong momentum will continue.

Industry Context

The results reflect the ongoing trends in the pharmaceutical industry, with strong growth in oncology and vaccines, while also highlighting the challenges of managing product lifecycles, as seen with the decline in LAGEVRIO sales. The restructuring program indicates a strategic shift towards new modalities and efficiency improvements, which is a common theme in the industry.

Comparison to Industry Standards

• Merck's KEYTRUDA sales growth of 19% is comparable to other leading oncology drugs, such as Bristol Myers Squibb's Opdivo, which has also seen strong growth in recent years, although specific growth rates vary.
• The 29% growth in GARDASIL/GARDASIL 9 sales is a strong performance in the vaccine market, where companies like Pfizer and GSK also compete with their own vaccine portfolios.
• The decline in LAGEVRIO sales is similar to what other companies have experienced with COVID-19 treatments as the pandemic has waned, such as Pfizer's Paxlovid.
• The restructuring program is similar to actions taken by other large pharmaceutical companies to optimize their manufacturing networks and reduce costs, such as Novartis and Sanofi.
• Merck's R&D spending of $30 billion is a significant investment, comparable to other large pharmaceutical companies like Roche and Johnson & Johnson, who also invest heavily in research and development.

Legal Proceedings

• The company incurred a $572.5 million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.

Stakeholder Impact

• Shareholders will be impacted by the lower earnings and restructuring costs, but may benefit from future growth and pipeline advancements.
• Employees may be affected by the restructuring program, with potential job losses or changes in roles.
• Customers will benefit from the continued development of new and innovative therapies and vaccines.
• Suppliers may be impacted by changes in the company's manufacturing network.
• Creditors will be impacted by the company's financial performance and restructuring activities.

Next Steps

• The company will continue to execute its restructuring program.
• Merck will focus on advancing its pipeline candidates through clinical trials and regulatory approvals.
• The company will integrate the recently acquired Harpoon Therapeutics.
• Merck will continue to monitor and manage the impact of foreign exchange rates.
• The company will provide updates on its progress in future financial reports.

Key Dates

Keywords

Merck, MRK, Pharmaceuticals, Oncology, Vaccines, KEYTRUDA, GARDASIL, LAGEVRIO, Restructuring, Financial Results, Earnings, Pipeline, FDA, Non-GAAP, EPS